Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

The impact of COVID-19 on chronic disease management and the implications for pharma marketing

The impact of COVID-19 on chronic disease management and the implications for pharma marketing

On February 11, 2020, COVID-19 was officially named by the World Health Organisation (WHO). Since then the novel coronavirus causing it, (a severe acute respiratory syndrome) has left its mark on almost every country in the world.

Therapy Watch, our syndicated PRF tracker, has been investigating the impact of COVID-19 on chronic disease management. In this white paper, we share some of the insights and consider future impact.

read more »

Excellence in oncology

Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers, physicians and patients. Payers are able to demonstrate that the treatment they are paying for will be of maximum value. Physicians feel confident that they are offering an effective drug, which is at the cutting-edge of medicine. And patients clearly benefit from a treatment programme that reduces the risk of unnecessary toxicities and offers them better outcomes.

read more »

China: How to strategise and win in the world's fastest changing healthcare market

China: How to strategise and win in the world's fastest changing healthcare market

In this paper, our experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch a brand effectively in this exciting region.

With a population of 1.4 billion people China has always been an attractive prize to the pharmaceutical industry. However, China has historically been a tough market to crack and few multinational companies have seen a good return on their investment. But in 2019, the 70th anniversary of the communist party’s victory, the outlook has changed completely and now pharma is rushing to leverage the many opportunities that China offers.

read more »

Are dual ARVs the new frontier in a maturing HIV market?

Are dual ARVs the new frontier in a maturing HIV market?

Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.

Therapy Watch Associate Director Raquel Nuñez, discusses continuing improvements in HIV therapies and the evolution of single-tablet regimens (STRs) over time.

read more »

  • Posted by Richard Head, Claire Richardson, Mariel Metcalfe
  • November 30, 2017
  • White papers

Patient centricity: Reality or rhetoric?

Patient centricity: Reality or rhetoric?

Everybody is talking about patient centricity, but what does it mean for those involved in market research, insights and business intelligence?

The term has certainly begun to filter through to the pharmaceutical market research industry. It was a hot topic at EphMRA conference in 2017, with a number of presentations from agencies, including some innovative new research offerings.

read more »